Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. April 2015 07:30 ET | Quelle: Advaxis

Advaxis Included Among "25 Top Immunotherapy Companies" in Newly Launched Loncar Cancer Immunotherapy Index (LCINDX)

PRINCETON, N.J., April 10, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that its stock has been added...
08. April 2015 07:30 ET | Quelle: Advaxis

Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer

PRINCETON, N.J. and KENILWORTH, N.J., April 8, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK),...
06. April 2015 07:30 ET | Quelle: Advaxis

Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer

PRINCETON, N.J., April 6, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it is entering into a...
26. März 2015 07:30 ET | Quelle: Advaxis

Advaxis to Present at the Jefferies Immuno-Oncology Summit

PRINCETON, N.J., March 26, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it will present at the...
19. März 2015 07:30 ET | Quelle: Advaxis

Advaxis Announces First Patient Treated in Phase 1/2 Dose-Escalation Study of ADXS-HPV for Recurrent Cervical Cancer

PRINCETON, N.J., March 19, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient was...
18. März 2015 13:12 ET | Quelle: Advaxis

Advaxis's Lm-LLO Immunotherapy Platform to be Featured in Three Poster Presentations at the 2015 American Association for Cancer Research Annual Meeting

Late Breaking Abstract to Highlight Enhanced Anti-Tumor Efficacy of ADXS-HPV (ADXS11-001) in Combination with OX40 and GITR Co-Stimulatory Molecule Monoclonal Antibodies Additional Late Breaking...
16. März 2015 07:30 ET | Quelle: Advaxis

Advaxis Presents Preliminary Data From a Phase 1/2 Trial of ADXS-HPV in HPV-Associated Anal Cancer in Combination With Chemoradiation Showing Complete Response and No Recurrences to Date in All Treated Patients

PRINCETON, N.J., March 16, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, presented preliminary data from the Phase 1/2 clinical study of its lead...
11. März 2015 07:30 ET | Quelle: Advaxis

Gynecologic Oncology Group (GOG) Commences Enrollment in Stage 2 of GOG-0265 Clinical Trial

PRINCETON, N.J., March 11, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the Gynecologic Oncology...
05. März 2015 07:30 ET | Quelle: Advaxis

Advaxis to Present at the 27th Annual ROTH Conference

PRINCETON, N.J., March 5, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor,...
02. März 2015 07:30 ET | Quelle: Advaxis

Advaxis to Present at the Cowen and Company 35th Annual Health Care Conference

PRINCETON, N.J., March 2, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor,...

Vorherige Seite

Nächste Seite